Claims
- 1. A pharmaceutical composition comprising a diuretic and an insulin sensitizer in a ratio of amounts by weight of 1:200 to 200:1.
- 2. A pharmaceutical composition according to claim 1 wherein said composition comprises one or more insulin sensitizers selected from the group consisting of troglitazone and pioglitazone, rosiglitazone, JTT-501, MCC-555, GI-262570, YM-440, KRP-297, T-174, NC-2100, BMS-298585, AZ-242 and NN-622 represented by the formulae below,
- 3. A pharmaceutical composition according to claim 2, wherein said diuretic comprises one or more compounds selected from the group consisting of acetazolamide, azosemide, amiloride, isosorbide, etacrynic acid, potassium canrenoate, chlortalidone, cyclopentiazide, spironolactone, torasemide, triamterene, trichlormethiazide, hydrochlorothiazide, hydroflumethiazide, piretanide, bumetanide, furosemide, benzylhydrochlorothiazide, penflutizide, methyclothiazide, metolazone and mefruside or selected from the group consisting of ENaC inibitors.
- 4. A pharmaceutical composition according to claim 1 wherein said insulin sensitizer is 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione or a pharmacologically acceptable salt thereof.
- 5. A pharmaceutical composition according to claim 1, wherein said diuretic comprises one or more compounds selected from the group consisting of acetazolamide, azosemide, amiloride, isosorbide, etacrynic acid, potassium canrenoate, chlortalidone, cyclopentiazide, spironolactone, torasemide, triamterene, trichlormethiazide, hydrochlorothiazide, hydroflumethiazide, piretanide, bumetanide, furosemide, benzylhydrochlorothiazide, penflutizide, methyclothiazide, metolazone and mefruside or selected from the group consisting of ENaC inibitors.
- 6. A pharmaceutical composition according to claim 4, wherein said diuretic is amiloride.
- 7. A pharmaceutical composition according to claim 1, wherein said diuretic is amiloride.
- 8. A method for the treatment or prophylaxis of diabetes mellitus, wherein said treatment or prophylaxis comprises administration in effective amounts, of a diuretic and an insulin sensitizer in a weight ratio of 1:200 to 200:1, simultaneously or at suitable intervals.
- 9. A method according to claim 8, wherein said diuretic comprises one or more compounds selected from the group consisting of acetazolamide, azosemide, amiloride, isosorbide, etacrynic acid, potassium canrenoate, chlortalidone, cyclopentiazide, spironolactone, torasemide, triamterene, trichlormethiazide, hydrochlorothiazide, hydroflumethiazide, piretanide, bumetanide, furosemide, benzylhydrochlorothiazide, penflutizide, methyclothiazide, metolazone and mefruside or said diuretic comprises one or more compounds selected from the group consisting of ENaC inhibitors.
- 10. A method according to claim 8, wherein said administration is simultaneous.
- 11. A method according to claim 8, wherein said administration is at a suitable interval.
- 12. A method according to claim 8, wherein said insulin sensitizer comprises one or more compounds selected from the group consisting of troglitazone and pioglitazone, rosiglitazone, JTT-501, MCC-555, GI-262570, YM-440, KRP-297, T-174, NC-2100, BMS-298585, AZ-242 and NN-622 represented by the formulae below,
- 13. A method according to claim 12, wherein said diuretic comprises one or more compounds selected from the group consisting of acetazolamide, azosemide, amiloride, isosorbide, etacrynic acid, potassium canrenoate, chlortalidone, cyclopentiazide, spironolactone, torasemide, triamterene, trichlormethiazide, hydrochlorothiazide, hydroflumethiazide, piretanide, bumetanide, furosemide, benzylhydrochlorothiazide, penflutizide, methyclothiazide, metolazone and mefruside.
- 14. A method according to claim 8, wherein said insulin sensitiser is 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione or a pharmacologically acceptable salt thereof.
- 15. A method according to claim 14, wherein said diuretic comprises one or more compounds selected from the group consisting of ENaC inhibitors.
- 16. A method according to claim 14, wherein said diuretic is amiloride.
- 17. A method for the prophylaxis of edema, cardiac enlargement, body fluid retention, or hydrothorax caused by an insulin sensitizer comprising administering the pharmaceutical composition of claim 1.
- 18. A method according to claim 17, wherein said diuretic comprises one or more compounds selected from the group consisting of acetazolamide, azosemide, amiloride, isosorbide, etacrynic acid, potassium canrenoate, chlortalidone, cyclopentiazide, spironolactone, torasemide, triamterene, trichlormethiazide, hydrochlorothiazide, hydroflumethiazide, piretanide, bumetanide, furosemide, benzylhydrochlorothiazide, penflutizide, methyclothiazide, metolazone and mefruside.
- 19. A method according to claim 17, wherein said diuretic comprises one or more compounds selected from the group consisting of ENaC inhibitors.
- 20. A method according to claim 17, wherein said diuretic is amiloride.
Priority Claims (1)
Number |
Date |
Country |
Kind |
2000-394424 |
Dec 2000 |
JP |
|
Parent Case Info
[0001] This is a Continuation-in-Part Application of International Application PCT/JP01/11296 filed Dec. 21, 2001, which is incorporated herein by reference in its entirety.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
PCT/JP01/11296 |
Dec 2001 |
US |
Child |
10606632 |
Jun 2003 |
US |